Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 8 May 2019 |
| Genmab Announces Data to be Presented at 2019 ASCO Annual Meeting | 17 Apr 2019 |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2019 | 16 Apr 2019 |
| Genmab Announces Submission of Supplemental New Drug Application in Japan for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma | 5 Apr 2019 |
| Genmab Announces Phase III Study Exploring Daratumumab as Maintenance Treatment in Newly Diagnosed Multiple Myeloma | 3 Apr 2019 |
| Genmab A/S has published its Articles of Association | 3 Apr 2019 |